Product
Pralatrexate
Aliases
Folotyn, Folotyn®, Pralatrexate Injection
Name
Folotyn
INN Name
Pralatrexate
FDA Approved
Yes
3 clinical trials
2 organizations
21 indications
2 documents
Indication
Peripheral T Cell LymphomaIndication
Anaplastic Large Cell LymphomaIndication
Recurrent Anaplastic Large Cell LymphomaIndication
Angioimmunoblastic T-Cell LymphomaIndication
Enteropathy-Associated T-Cell LymphomaIndication
Recurrent Follicular LymphomaIndication
Peripheral T-cell lymphomaIndication
CTCLIndication
Hepatosplenic T-Cell LymphomaIndication
Mycosis FungoidesIndication
Recurrent Peripheral T-Cell LymphomaIndication
NOSIndication
Follicular LymphomaIndication
Peripheral T-Cell LymphomaClinical trial
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell LymphomaStatus: Recruiting, Estimated PCD: 2030-07-01
Clinical trial
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-05-03
Clinical trial
Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or PralatrexateStatus: Recruiting, Estimated PCD: 2025-06-30
Document
DailyMed Label: FolotynOrganization
Acrotech Biopharma IncDocument
DailyMed Label: PralatrexateOrganization
Fresenius Kabi USA, LLC